Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of CoV-2 SAM (LNP) Vaccine in Healthy Adults
NCT04758962Phase 1Completed
- Sponsor
- GSK
- Start
- Feb 2021
- Primary completion
- Jun 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SARS-CoV-2 self-amplifying messenger RNA lipid nanoparticle vaccine in coronavirus disease 2019 (COVID-19), sponsored by GSK. Primary endpoints: Number of Participants With Solicited Administration Site Adverse Events, Number of Participants With Solicited Systemic Adverse Events and 5 more. Started Feb 2021; status: completed.
02
Drugs
SARS-CoV-2 self-amplifying messenger RNA lipid nanoparticle vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04758962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04758962.